- Home
- NA vs TNYA Comparison
NA vs TNYA Comparison
Compare NA & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- TNYA
- Stock Information
- Founded
- NA 2019
- TNYA 2016
- Country
- NA China
- TNYA United States
- Employees
- NA N/A
- TNYA N/A
- Industry
- NA Semiconductors
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- NA Technology
- TNYA Health Care
- Exchange
- NA Nasdaq
- TNYA Nasdaq
- Market Cap
- NA 77.6M
- TNYA 74.5M
- IPO Year
- NA 2022
- TNYA 2021
- Fundamental
- Price
- NA $3.50
- TNYA $0.46
- Analyst Decision
- NA
- TNYA Strong Buy
- Analyst Count
- NA 0
- TNYA 6
- Target Price
- NA N/A
- TNYA $8.60
- AVG Volume (30 Days)
- NA 17.5K
- TNYA 2.3M
- Earning Date
- NA 03-25-2025
- TNYA 05-07-2025
- Dividend Yield
- NA N/A
- TNYA N/A
- EPS Growth
- NA N/A
- TNYA N/A
- EPS
- NA N/A
- TNYA N/A
- Revenue
- NA $5,561,770.00
- TNYA N/A
- Revenue This Year
- NA N/A
- TNYA N/A
- Revenue Next Year
- NA N/A
- TNYA N/A
- P/E Ratio
- NA N/A
- TNYA N/A
- Revenue Growth
- NA N/A
- TNYA N/A
- 52 Week Low
- NA $2.75
- TNYA $0.36
- 52 Week High
- NA $13.86
- TNYA $4.29
- Technical
- Relative Strength Index (RSI)
- NA 33.69
- TNYA 48.93
- Support Level
- NA $3.33
- TNYA $0.43
- Resistance Level
- NA $4.06
- TNYA $0.46
- Average True Range (ATR)
- NA 0.41
- TNYA 0.04
- MACD
- NA -0.04
- TNYA 0.01
- Stochastic Oscillator
- NA 13.49
- TNYA 71.43
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.